experience omalizumab in higher HRQoL the UK/EU in day-to-day licensed symptoms than population patients on collected data standard care on the quality of only. improvement life Exacerbations in HRQoL are associated conferred by with omalizumab HRQoL, that is used in independent of the analysis. treatment. Costs of omalizumab Resource use Resource estimated using associated use and the dose with the costs distribution administration observed in and monitoring
quality of life experience higher HRQoL in day-to-day symptoms than patients on standard care only. Exacerbations are associated with HRQoL, independent of treatment. omalizumab in the UK/EU licensed population collected data on the improvement in HRQoL conferred by omalizumab that is used in the analysis. Resource use and costs Costs of omalizumab estimated using the dose distribution observed in Resource use associated with the administration and monitoring
1-s2.0-S1098301514019330-mmc1.docx